Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR 1,151.80
-19.15 (-1.64%)
Feb 21, 2025, 3:29 PM IST
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,048 employees as of March 31, 2024. The number of employees increased by 1,185 or 4.58% compared to the previous year.
Employees
27,048
Change (1Y)
1,185
Growth (1Y)
4.58%
Revenue / Employee
11.51M INR
Profits / Employee
1.98M INR
Market Cap
959.71B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Divi's Laboratories | 9,741 |
| Cipla | 27,764 |
| Mankind Pharma | 19,540 |
| Apollo Hospitals Enterprise | 83,147 |
| Zydus Lifesciences | 26,921 |
| Aurobindo Pharma | 26,015 |
| Alkem Laboratories | 17,432 |
Dr. Reddy's Laboratories News
- 3 days ago - Nifty 50 top losers today on February 19: Dr. Reddy’s Laboratories, TCS, Infosys and Hindustan Unilever - Business Upturn
- 16 days ago - Dr Reddy’s inks exclusive deal for cancer drug in US, EU - The Times of India
- 16 days ago - Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy - Seeking Alpha
- 16 days ago - Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire
- 16 days ago - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. - PRNewsWire
- 16 days ago - Dr. Reddy’s signs $131.6 million deal with Henlius to commercialize multiple myeloma biosimilar in US and Europe - Business Upturn
- 16 days ago - Nifty 50 top gainers today on February 6: Cipla, ITC Hotels, Dr. Reddy’s Laboratories, HDFC Life and more - Business Upturn
- 23 days ago - Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns - Seeking Alpha